These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 37230531

  • 41. Combined Early and Late [68Ga]PSMA-HBED-CC PET Scans Improve Lesion Detectability in Biochemical Recurrence of Prostate Cancer with Low PSA Levels.
    Hohberg M, Kobe C, Täger P, Hammes J, Schmidt M, Dietlein F, Wild M, Heidenreich A, Drzezga A, Dietlein M.
    Mol Imaging Biol; 2019 Jun; 21(3):558-566. PubMed ID: 30105521
    [Abstract] [Full Text] [Related]

  • 42. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer.
    Meijer D, Eppinga WSC, Mohede RM, Vanneste BGL, Meijnen P, Meijer OWM, Daniels LA, van den Bergh RCN, Lont AP, Ettema RH, Oudshoorn FHK, van Leeuwen PJ, van der Poel HG, Donswijk ML, Oprea-Lager DE, Schaake EE, Vis AN.
    Eur Urol Oncol; 2022 Apr; 5(2):146-152. PubMed ID: 35074282
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
    Lenis AT, Pooli A, Lec PM, Sadun TY, Johnson DC, Lebacle C, Fendler WP, Eiber M, Czernin J, Reiter RE, Calais J.
    Eur Urol Oncol; 2022 Oct; 5(5):544-552. PubMed ID: 32958451
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. A Review on the Current State and Future Perspectives of [99mTc]Tc-Housed PSMA-i in Prostate Cancer.
    Brunello S, Salvarese N, Carpanese D, Gobbi C, Melendez-Alafort L, Bolzati C.
    Molecules; 2022 Apr 19; 27(9):. PubMed ID: 35565970
    [Abstract] [Full Text] [Related]

  • 48. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (68 Ga-PSMA) positron-emission/computed tomography after radical prostatectomy with pathological node-positive extended lymph node dissection.
    Huits TH, Luiting HB, van der Poel HG, Nandurkar R, Donswijk M, Schaake E, Vogel W, Roobol MJ, Wit E, Stricker P, Emmett L, van Leeuwen PJ.
    BJU Int; 2020 Jun 19; 125(6):876-883. PubMed ID: 32181951
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Incremental Impact of [68 Ga]Ga-PSMA-11 PET/CT in Primary N and M Staging of Prostate Cancer Prior to Curative-Intent Surgery: a Prospective Clinical Trial in Comparison with mpMRI.
    Szigeti F, Schweighofer-Zwink G, Meissnitzer M, Hauser-Kronberger C, Hitzl W, Kunit T, Forstner R, Pirich C, Beheshti M.
    Mol Imaging Biol; 2022 Feb 19; 24(1):50-59. PubMed ID: 34519966
    [Abstract] [Full Text] [Related]

  • 52. 68 Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer.
    Pfister D, Haidl F, Nestler T, Verburg F, Schmidt M, Wittersheim M, Steib F, Heidenreich A.
    BJU Int; 2020 Dec 19; 126(6):679-683. PubMed ID: 32531840
    [Abstract] [Full Text] [Related]

  • 53. SPECT-CT Imaging with [99mTc]PSMA-T4 in patients with Recurrent Prostate Cancer.
    Sergieva S, Mangaldgiev R, Dimcheva M, Nedev K, Zahariev Z, Robev B.
    Nucl Med Rev Cent East Eur; 2021 Dec 19; 24(2):70-81. PubMed ID: 34382671
    [Abstract] [Full Text] [Related]

  • 54. Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer.
    Schmuck S, Nordlohne S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, Ross TL, Bengel FM, Derlin T.
    Eur J Nucl Med Mol Imaging; 2017 Jun 19; 44(6):960-968. PubMed ID: 28280856
    [Abstract] [Full Text] [Related]

  • 55. The efficacy of 99mTc-HYNIC-PSMA SPECT/CT in detecting primary lesions and metastasis in newly diagnosed prostate cancer.
    Wang T, Zhao L, Qiao W, Sun N, Zhao J, Xing Y.
    Front Oncol; 2023 Jun 19; 13():1165694. PubMed ID: 37333816
    [Abstract] [Full Text] [Related]

  • 56. Metastases-yield and Prostate-specific Antigen Kinetics Following Salvage Lymph Node Dissection for Prostate Cancer: A Comparison Between Conventional Surgical Approach and Prostate-specific Membrane Antigen-radioguided Surgery.
    Knipper S, Tilki D, Mansholt J, Berliner C, Bernreuther C, Steuber T, Maurer T, Graefen M.
    Eur Urol Focus; 2019 Jan 19; 5(1):50-53. PubMed ID: 30292421
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Multiphasic 68Ga-PSMA PET/CT in the Detection of Early Recurrence in Prostate Cancer Patients with a PSA Level of Less Than 1 ng/mL: A Prospective Study of 135 Patients.
    Beheshti M, Manafi-Farid R, Geinitz H, Vali R, Loidl W, Mottaghy FM, Langsteger W.
    J Nucl Med; 2020 Oct 19; 61(10):1484-1490. PubMed ID: 32060214
    [Abstract] [Full Text] [Related]

  • 59. 99mTc-PSMA SPECT/CT Versus 68Ga-PSMA PET/CT in the Evaluation of Metastatic Prostate Cancer.
    Fallahi B, Khademi N, Karamzade-Ziarati N, Fard-Esfahani A, Emami-Ardekani A, Farzanefar S, Eftekhari M, Beiki D.
    Clin Nucl Med; 2021 Feb 01; 46(2):e68-e74. PubMed ID: 33234922
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.